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R E V I E W
GVHD and relapse are two major causes of deathafter HPC transplantation.1 The most efficientmethod for prevention of GVHD consists of T-cell depletion of the graft.2-5 However, this usu-
ally leads to greatly increased risks of leukemia relapse,3,6,7
due to the loss of the graft-versus-leukemia (GVL) effect that
has been recognized as an important component of the
anti-leukemic efficacy of allogeneic HPC transplantation,
particularly for chronic myelogenous leukemia (CML). The
demonstration of this GVL effect and of the primordial role
of T-lymphocytes led investigators to transfuse donor lym-
phocytes to CML patients relapsing after HPC transplanta-
tion.8-14 Indeed, donor lymphocyte infusions (DLIs) have in-
creasingly been used to treat relapse after HPC
transplantation not only for CML but also for acute myeloid
leukemia (AML), acute lymphoblastic leukemia (ALL),
myelodysplastic syndrome (MDS), multiple myeloma
(MM), and non-Hodgkin’s lymphoma.15-22
DEMONSTRATION OF THE GVL EFFECT
AFTER HPC TRANSPLANTATION
A GVL effect was first posited in 1956 on the basis of mu-
rine experiments: mice receiving syngeneic transplants af-
ter the injection of leukemic cell lines and total body irra-
diation almost uniformly relapsed, whereas mice receiving
allogeneic transplants developed GVHD but had a lower
incidence of relapse.23 The first landmark reports of GVL
effects in human allograft recipients were published by Weiden
et al. in 197924 and 1981.25 Their observations were con-
firmed by a large retrospective study of 2254 patients receiv-
ing HLA-identical sibling bone marrow (BM) transplants for
various hematologic malignancies.7 A lower rate of relapse
was observed in recipients of non-T-cell-depleted BM
transplants than in recipients of T-cell-depleted allografts
or syngeneic BM transplants. In that study, the GVL effect
was also evidenced by the lower rate of relapse in patients
with GVHD (particularly chronic GVHD in AML and CML
patients and acute GVHD in ALL patients), although the
GVL reaction was not restricted to patients with GVHD.
The International Bone Marrow Transplant Registry
also compared HLA-identical sibling transplants in 731 re-
cipients of T-cell-depleted BM transplants and 2480 recipi-
ents of non-T-cell-depleted BM transplants and determined
the relative risk of relapse after adjusting for the incidence
and severity of acute and chronic GVHD.3 The relative risks
of relapse with and without T-cell depletion for AML and
ALL in first remission and CML in chronic phase were 1.66
(NS), 1.55 (NS), and 4.87 (p<0.0001), respectively. Finally,
the GVL effect was also demonstrated by the evolution of
minimal residual disease after transplant, which often
ceases to be detectable only 6 to 12 months after BM trans-
plant,26 and the occurrence of GVL activity with or without
GVHD after cessation of GVHD prophylaxis without DLI
after posttransplant relapse.27-29
Mechanisms of GVL
Cells involved in the GVL effect. MHC-restricted CD4+ and
CD8+ T cells and NK cells are probably all involved in the
process of both GVL and GVHD.30-32 It is likely that cells
implicated in the GVL effect vary as a function of the he-
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matologic malignancies involved, depending upon their
MHC expression33 and the nature of antigens presented.
However, the recognition by CD4+ cells of peptide antigens
presented through MHC class II molecules on host cells is
essential in initiating a response against leukemia.34 In trans-
plant recipients with CML, the most often identified are
CD4+ T-cell lines or clones, which inhibit the growth of leu-
kemic progenitors or lyse them, either through direct cy-
totoxicity or cytokine-mediated anti-leukemic effects.35,36 More-
over, the efficacy of CD8+ cell depletion in reducing the risk
of GVHD without impairing the GVL effect, be it by deple-
tion of the original graft37,38 or that of DLI after relapse,39,40
suggests a primary role for CD4+ cells in the GVL effect (par-
ticularly in CML, but also in MM40) and a primary role for
CD8+ cells in GVHD.
Confirming these findings, Nagler et al.41 recently showed
that selective depletion of CD4+ cells does not prevent GVHD.
However, these observations do not deny the role of CD8+
cells in the GVL effect. Even after CD8+ cell depletion, about
0.6 × 106 CD3+CD8+ cells per kg are transfused,14 and more-
over, transfused CD4+ cells may recruit CD8+ cells in the
host. In addition, CD8+ T-cell clones with cytotoxic activity
against leukemic cells have been identified,42 and cytoloxic
T-lymphocyte(s) (CTLs) directed specifically against minor
histocompatibility antigens (mHA)43 or EBV-related anti-
gens44 are CD8+. To provide help to CD8+ cells (that recog-
nize antigenic peptides complexed with MHC class I mol-
ecules), CD4+ cells require co-stimulation with molecules
of the B7 family.45,46 Many tumors, including most human
leukemias, lack expression of B7, which contributes to the
absence of immune recognition in these diseases; in such
diseases, B7 gene transfer could be an attractive approach.46
Despite the increased risk of relapse after T-cell-de-
pleted HPC transplantation that leaves NK cells behind in
the graft, NK cells may still play a role in the GVL effect in
some situations. Inhibition of NK cell lysis is mediated by
membrane receptors with different specificities for MHC
class I alleles. In particular, killer cell inhibitory receptors
(KIRs) recognize epitopes shared by HLA-C (Cw2, 4, 5, and
6 for KIR2DL2 vs. Cw1, 3, 7, and 8 for KIR2DL1) or HLA-Bw4
(KIR3DL1).47 Ruggeri et al.48 recently studied the role of KIR
epitope incompatibility in HLA-mismatched T-cell-depleted
HPC transplantation and detected high frequencies of NK
cell clones, which killed the recipient target cells in patients
given cells from KIR epitope-incompatible donors. More-
over, these patients had a lower incidence of myeloid re-
lapse than patients given cells from KIR epitope-compatible
donors, which suggests a GVL effect mediated by donor-derived
NK cells. In mice, adoptive immunotherapy with MHC-mis-
matched or donor-activated NK cells administered after BM
transplant was shown to provide a strong GVL effect,49 and
depletion of NK cells from the graft enhanced the relapse
rate of leukemic cell lines shown in vitro to be NK cell-sen-
sitive.50 These results suggest that NK cells may play a role
in the GVL effect when leukemic cells are NK cell-sensitive
(i.e., in myeloid malignancies) and when leukemic cells do
not express MHC class I KIR ligands of the donor NK cells.
Antigens involved in the GVL effect. Several studies
have shown that response to DLI is associated with conver-
sion from a mixed chimeric state before transfusion to com-
plete donor hematopoiesis after DLI.11,13,16,40,51 Moreover,
DLI in patients who do not have residual donor hemato-
poiesis induces severe marrow aplasia, which may be re-
solved by the transfusion of donor stem cells.15,52 Finally, DLI
can displace residual host stem cells in case of the recur-
rence of nonmalignant disease after allogeneic HPC trans-
plantation.53 Taken together, these observations suggest that
the GVL reaction associated with DLI is likely directed against
allospecific antigens rather than disease-specific targets.
The mHA may be a target of the GVL response,15,40,52,54
but other, unrecognized targets may also exist. The mHA are
polymorphic antigens that are inherited independently from
HLA antigens and that may be recognized by alloreactive T
cells.54 One important characteristic of mHA is their tissue-
restricted distribution. Some, such as the H-Y antigen, are
expressed on all MHC-bearing cells, whereas the expression
of others (HA-1, HA-2, HA-5, HB-1, etc.) is restricted to the
hematopoietic and lymphoid tissues.43 Mutis et al.54 recently
generated HA-1- and HA-2-specific CTLs from HA-1- and/
or HA-2-negative healthy blood donors by using HA-1- and
HA-2-synthetic peptide-pulsed antigen dendritic cells. These
CTLs displayed specific cytotoxic activity against target cells
expressing HA-1 and/or HA-2 (including leukemic cells from
ALL and AML patients) but not against nonhematopoietic
cells. Warren et al.43 isolated other mHA, not only HLA-A2
or HLA-B7 but also HLA-A3, -A11, -B8, -B53, and -Cw7. Most
of these mHA did not lyse dermal fibroblasts, which sug-
gests that the transfer of these mHA-specific CTLs could
have GVL activity without causing GVHD. However, some
caution is necessary, as recent studies recognized a significant
association of an HA-1 mismatch between donor and recipi-
ent and the occurrence of GVHD.55,56 Moreover, data from
in vitro cytolytic assays against fibroblasts could underes-
timate the expression of mHA in tissues in vivo and thus
underestimate their potential for inducing GVHD.43
In treatment of malignancies in which translocations
result in fusion proteins (CML and some ALL with t[9;22],
AML M2 with t[8;21], AML M3 with t[15;17], and AML M4
with inv 16), these fusion proteins represent ideal targets
for adoptive immunotherapy, because they are not present
in normal cells.  The rearrangement of the bcr and abl genes
in the Philadelphia chromosome results in the expression
of BCR-ABLb3a2 (the most frequently observed) or BCR-ABLb2a2
proteins. There are no convincing data that BCR-ABLb3a2 or
BCR-ABLb2a2 proteins are targets in DLI-mediated GVL ef-
fects. However, peptides from the joining region of b3a2
have been identified that bind to HLA-A3, -A11, -B8, or both
HLA-A3 and –A11 molecules and that elicit CTLs in vitro.57-59
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Several studies57,58 failed to show junctional peptide presen-
tation by HLA-A2, the most frequent MHC class I in humans,
but Yotnda et al.60 recently identified a junctional nonapeptide
that binds to HLA-A2 molecules and elicits primary CTL
responses in vitro. Moreover, CTLs that are specific for this
junctional peptide were found at high frequency in 5 of 21
CML patients.60 In vitro generation of specific CTLs by do-
nor dendritic cells pulsed with b3a2 peptide was proposed
as a way to increase the GVL effect without exaggerating
GVHD. The ability of normal donor peripheral blood lym-
phocytes stimulated with b3a2 peptide-loaded autologous
dendritic cells to lyse b3a2-positive marrow cells derived
from an HLA-identical sibling of a CML patient was recently
reported.59 However, HLA restriction of the b3a2-specific re-
sponse may be responsible for the absence of cytotoxic ac-
tivity induced by CTLs from some patients.59
In cases of B-cell lymphoma and MM, it has been pos-
sible to immunize the donor to the antibody idiotype of the
lymphoma61 or the MM,62-64 after which the immunity could
be transferred. However, the clinical benefits of such an
approach remain to be determined.
Finally, in virus-induced malignancies, adoptive immuno-
therapy against virus-derived antigens may be effective. Particu-
larly after allogeneic HPC transplantation, CTLs directed against
EBV-derived antigens were effective in preventing65 or treating66-
68 EBV-induced lymphomas. Adoptive immunotherapy against
other EBV-associated malignancies (Hodgkin’s disease or na-
sopharyngeal carcinoma) in which less immunogenic EBV an-
tigens occur is currently investigated.69
DLI IN PATIENTS WITH RELAPSED
MALIGNANCY AFTER ALLOGENEIC HPC
TRANSPLANTATION
Efficacy of DLI
The apparent power of the GVL effect and its presumed
mediation by donor lymphocytes led several groups to
transfuse donor WBCs to patients with relapsed leukemia
after HPC transplantation. Two large multicenter studies
have reviewed the results from 27 transplant centers in
Europe15 and 25 in North America16 (Table 1). In these stud-
ies, DLI induced a complete remission (CR) in about 64 per-
cent of the patients with CML and in 20 to 38 percent of the
patients with AML or MDS. In patients with CML, the re-
sponse rate was highest when lymphocytes were transfused
in early cytogeneic relapse (79%) and lowest when they
were transfused during accelerated-phase CML (hemato-
logic relapse)or blast crisis (19%). The median time to
achieve a cytogenetic remission was 85 days (range, 28-241)
for patients with CML (the time to achieve molecular remis-
sion can be prolonged) and 34 days (range, 16-99) for pa-
tients with AML.16 Remissions were durable in patients
treated for CML in the chronic-phase (probability of con-
tinuous remission, 87% at 3 years), but almost 100 percent
of patients treated for advanced-phase CML later re-
lapsed,15 and less than 30 percent of them survived at the
time of the analysis.52 The median duration of remission in
AML patients with complete responses was 17.9 months,16
but the longest remissions lasted for 2 to 4 years.52
DLI can also induce CRs in patients with MM. In a ret-
rospective study including 13 patients who underwent a
total of 29 DLIs, 8 patients responded (4 patients achieved
a partial remission and 4 achieved CR).20 In this study, acute
and chronic GVHD occurred in 66 and 56 percent of all
patients and in 87 and 85 percent of the responders, respec-
tively. However, unlike that in patients with early-stage
CML, the response in patients with MM was not consis-
tently durable. Moreover, the anti-tumor effect was essen-
tially directed toward the BM, and development of plas-
mocytomas could occur while the BM and serum
paraprotein showed evidence of a response.20
In contrast to those in myeloid forms of leukemia, re-
sponses were rare in ALL and in high-grade lymphoma
(Table 1).15,16,52 It has been speculated that the better re-
sponse in chronic-phase CML may be explained by the fact
that dendritic cells, the most potent antigen-presenting
cells, are part of the leukemic clone in CML52 and are ca-
pable of inducing a strong T-cell response.70 In contrast, the
malignant cells in accelerated-phase CML or in acute leu-
kemia may be more inappropriate antigen-presenting cells
TABLE 1. Response to DLI in three studies of patients with relapsed hematologic malignancies
Study 115 Study 216 Study 320 Total of the three studies
Percentage of
Evaluable Complete Evaluable Complete Evaluable Complete Evaluable Complete complete
Disease patients responses patients responses patients responses patients responses responses
CML  111 73 55 33 166 106 64
   Cytogenetic relapse 0 25 19 03 03 028 022 79
   Hematologic relapse 0 72 53 34 25 106 078 74
   Advanced-phase 0 14 01 18 05 032 006 19
AML 37 09 39 06 076 015 20
MDS 00 8 03 05 02 013 05 38
ALL   20 01 11 02 031 003 10
MM 007 01 04 02 13 4 024 007 29
Non-Hodgkin’s lymphoma 002 01 06 10 008 001 13
   Total 185 88 120 45 13 4 318 137 43
ADOPTIVE IMMUNOTHERAPY WITH DLIS
Volume 40, April 2000   TRANSFUSION   471
and may lead to the induction of anergy rather than to an
anti-leukemic T-cell response.71 The reasons for the observed
differences in response rates among diseases should be fur-
ther investigated. Finally, a recent report suggested that
chemotherapy given after DLI did not nullify the ability of
the lymphocytes to mediate GVHD as well as GVL effects.72
Complications of DLI
Complications of DLI include acute and chronic GVHD and
transient marrow aplasia. Acute GVHD occurs in about 60
percent of the patients (grade 3 or 4 in about 20%) and is
significantly correlated with CR.16 Chronic GVHD also oc-
curs in about 60 percent of the patients (extensive in 30%)
and is also significantly correlated with response.16 However
CR may be observed in the absence of GVHD, which sug-
gests that the GVL response may be independent of the
clinical development of GVHD.16,40,52 The risk of GVHD (but
not the efficacy of DLI to induce CR) correlates with the
dose of lymphocytes transfused. The MNC dose transfused
varies between 0.1 to 11 × 108 per kg of body weight.15,16 It
is possible to reduce the risk of GVHD without impairing
the GVL effect by starting with a low dose of T cells and in-
creasing the dose in a stepwise fashion if there is no re-
sponse.13 It is interesting that the involvement of GVHD in
the organs is different from that seen after HPC transplan-
tation, and, in particular, the skin is less affected.52
Marrow aplasia, due to a direct cytotoxic effect of trans-
fused lymphocytes on hematopoietic cells in the host, oc-
curs in about 20 percent of the patients. It is significantly
less frequent in patients with cytogenetic relapse (11%) than
in those with hematologic relapse of CML (50%),15 because
residual hematopoiesis is still of donor origin in patients
with cytogenetic relapse. Marrow aplasia resolved without
treatment in about 50 percent of the patients and resolved
with G–CSF in about 30 percent.16 However, in case of se-
vere pancytopenia, the transfusion of marrow or blood pro-
genitor cells of the donor without further conditioning may
correct myelosuppression,15 with the possible exception of
that in patients with chronic GVHD.
The primary cause of death after DLI is progressive
disease, which is responsible for
about 77 percent of deaths (Table
2).15,16 Other causes include GVHD
(8%), infection (5%), pancytopenia
(4%), and the combination of
GVHD and pancytopenia (2.5%).
Pretreatment factors
influencing response of
recurrent CML to DLI
Multivariate analysis of these two
multicenter series15,16 found that a
pre-DLI status of chronic-phase
(as opposed to more advanced
disease) was favorable to a complete response to DLI. An-
other favorable factor was an interval between HPC trans-
plantation and DLI of less than 2 years.16 The role of T-cell
depletion of the graft and of post-BM transplantation
chronic GVHD is controversial. Finally, the T-cell dose trans-
fused did not influence response to DLI.15,16,52
MANIPULATIONS OF DLI
Immunotherapy with escalating doses of donor
lymphocytes
Immunotherapy with escalating doses of donor lympho-
cytes was evaluated in a prospective study of 22 patients
with relapsed CML after allogeneic BM transplantation.13
Patients received escalating doses of donor lymphocytes
(from 1 × 105 to 5 × 108/kg) at 4- to 33-week intervals. Nine-
teen of the 22 patients achieved CR, and T-cell doses as low
as 1 × 107 per kg were shown to achieve complete responses
(in patients with molecular, cytogenetic, and even acceler-
ated-phase relapse) with a low risk of GVHD (only 1/8 CR
patients vs. 8/11 responders receiving >5 × 107/kg) (Table
3). In this study, and in accordance with previous stud-
ies,15,52 there was no real evidence of a dose–response rela-
tionship in DLI. Low-dose therapy was primarily efficient
in patients with molecular relapses.
Because there is a tendency for molecular positivity to
come and go spontaneously, some caution should be ob-
served in the interpretation of the role of DLI in correcting
molecular relapses. Another recent study compared the
efficacy and safety of a single transfusion of a relatively large
dose of donor lymphocytes (bulk-dose regimen) and those
of the transfusion of smaller doses repeated as necessary
at 3-month intervals (escalating-dose regimen) in CML
patients relapsing after allografting.73 In this study, the CR
rate at 2 years was higher (but not significantly so) and the
risk of acute GVHD significantly lower in patients allocated
to the escalating-dose regimen, even when the total num-
ber of cells administered was similar. However, a strategy
in which increasing numbers of lymphocytes are transfused
must be viewed cautiously, as the median time to achieve
TABLE 2. Causes of death after DLI in two studies
Study 115 Study 216 Total of the two studies
Percentage
Evaluable Total Evaluable Total Evaluable Total Percentage of patients
Cause of death  patients  deaths  patients deaths patients  deaths who died
Progressive 109 47 124 70 233 117 50
   disease
GVHD 109 04 124 08 233 012 05
Pancytopenia 109 06 124 –* 233 006 03
GVHD and 109 04 124 –* 233 004 02
   pancytopenia
Infection 109 01 124 06 233 007 03
Hemorrhage 109 01 124 01 233 002 01
Other 109 01 124 02 233 003 01
   Total 109 64 124 87 233 151 65
* In 4 patients, pancytopenia was associated with fatal GVHD or infection.
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cytogenetic CR was 85 days and the time to achieve molecu-
lar CR was even greater.
Immunotherapy with DLIs depleted of CD8+ cells
Unlike T-cell depletion of donor marrow, which increases
the risk of relapse (particularly in patients with CML), se-
lective CD8+ T-cell depletion of the graft significantly re-
duced the risk of GVHD without losing the GVL effect.37,38
These observations led investigators to transfuse donor lym-
phocytes depleted of CD8+ cells. One study included 10
patients with relapsed CML after allogeneic BM transplant
(1 cytogenetic relapse, 4 in chronic phase, 2 in accelerated
phase, and 3 in blast crisis).14 Patients received DLIs de-
pleted of CD8+ cells and containing 0.9 ± 0.3 × 108 MNCs
per kg (0.6 ± 0.4 × 106 CD3+CD8+ cells/kg). Six patients achieved
CR (1/1 with cytogenetic relapse, 4/4 with chronic-phase
CML, and 1/2 with accelerated-phase CML), whereas only
three patients developed GVHD, which responded well to
systemic steroid therapy. Recently, another study of 40 pa-
tients evaluated the response to 0.3 to 1.5 × 108 CD4+ cells
per kg after depletion of CD8+ cells.40 Fifteen (87%) of 19
patients with early chronic-phase CML achieved a com-
plete cytogenetic response, 5 of 6 with MM obtained a more
than 50-percent decrease in their paraprotein level, and 1
with MDS also responded. GVHD occurred in 6 (22%) of 27
patients receiving 0.3 × 108 CD4+ cells per kg and in 6 (55%)
of 11 patients who received >1.0 × 108 CD4+ cells per kg.
Transfusion of donor lymphocytes transfected with
a suicide gene
Another interesting approach consisted of in vitro insertion
of a suicide gene, the HSV-tk gene (which selectively phos-
phorylates gancyclovir, leading to its incorporation into
DNA and causing cell death) into lymphocytes, allowing
their elimination by gancyclovir if severe GVHD develops
after DLI.74-76 A clinical study using this approach was re-
cently reported.75 Eight patients who relapsed or developed
EBV-induced malignancies after allogeneic BM transplant
received genetically modified DLIs. An antitumor activity
was observed in five patients, and two achieved a CR. GVHD
developed in three patients, which could be efficiently con-
trolled by the gancyclovir elimination of transfused cells.
Moreover, transduced lymphocytes survived for up to 12
months. Unfortunately, the induction of a strong immune
response against genetically modified cells and partial re-
sistance to gancyclovir-mediated elimination of transduced
cells in chronic GVHD was observed. This justifies the de-
velopment of new nonimmunogenic and non-cell cycle-
dependent suicide genes.77
Transfusion of IL-2-activated donor lymphocytes
Data from murine models and humans suggest that GVL
effects may be increased by in vivo activation of lympho-
cytes with rHuIL-2. These data led Slavin et al.17 to activate
donor lymphocytes in vitro and/or in vivo by using rHuIL-2 in
patients with tumor cells that are resistant to standard DLIs.
Complete responses were obtained in 10 of the 16 patients
(4/6 ALL patients, 0/3 AML patients, 5/6 CML patients, and
1 MDS patient). All 4 of these patients with ALL and 4 of
these 5 patients with CML were still alive and free of dis-
ease 13 to 95 months (median, >2 years) after cell therapy.
These results appear to be particularly interesting in pa-
tients with ALL, who classically respond poorly to DLI.
DLI to prevent relapse after allogeneic HPC
transplantation
As DLIs are particularly effective when performed in early
relapse,15,16 it might be more efficient to give donor lympho-
cytes before relapse, a time when minimal residual disease
is still present. However, DLIs given early after BM trans-
plant are associated with a very high risk of severe acute
GVHD, which precludes any improvement in the control of
leukemia.80 This dilemma between the risk of GVHD and
the benefit of a GVL effect may be resolved by delaying DLI
until graft-versus-host tolerance has been established.15
This approach has been proposed after T-cell-depleted HPC
transplantation.81-83 Naparstek et al.83 recently compared
three schedules of DLI (early, starting on Day 1; intermedi-
ate, starting in Week 4; and late, starting in Week 8) for pre-
vention of relapse in 108 patients after T-cell-depleted BM
transplant. In this study, patients receiving late DLI had sig-
nificantly greater survival and decreased risk of GVHD than
did those given DLI earlier. Barrett et al.82 recently demon-
strated a strong GVL effect with a low risk of acute GVHD
after the return of 2 × 106 T cells per kg on Day 30 and 5 ×
107 T cells per kg on Day 45 after T-cell-depleted BM trans-
plant, using cyclosporine prophylaxis. In this study, disease-
free survival was comparable to that currently achieved in
T-cell-replete transplants in similar pa-
tients.82 However, the transfusion of 107
donor T cells per kg on Day 30 gave
poorer results because of a high inci-
dence of severe GVHD. Another recent
report evaluated the feasibility of DLI 2
months after allogeneic BM transplant
with selected CD34+ cells.84 Of 16 pa-
tients included in this study, 6 under-
went DLI. The first 3 received 5 × 106
TABLE 3. Results of a study13 of immunotherapy with escalating doses of
donor lymphocytes
Number of patients achieving CR
Response to DLI at four T-cell doses per kg
Stage of CML Cases CRs 1 × 107 5 × 107 1 × 108 5 × 108
Molecular relapse 02 02 2 2 0 0
Cytogenetic relapse 06 06 5 1 0 0
Chronic phase 10 09 0 3 2 4
Accelerated phase 04 02 1 0 1 0
Total 22 19 8 4 3 4
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CD3+ cells per kg and all developed serious complications
(grade 3 GVHD [n = 3] and severe aplasia [n = 1]). The other
3 received 1 × 105 CD3+ cells per kg, and only 1 developed
GVHD. Taken together, these results suggest that DLI as a
method of preventing relapse after allogeneic HPC trans-
plantation is feasible, but its benefits remain to be demon-
strated in large clinical trials.
Transfusion of tumor-specific CTLs
Several investigators have reported that DLI can cure EBV-
induced lymphoproliferative disease after allogeneic BM
transplant in more than 50 percent of patients.66,68 However,
several patients developed moderate to severe GVHD. To di-
minish the risk of GVHD, researchers at one institution44,65,67,85,86
transfused specific anti-EBV donor T cells induced ex vivo with
EBV-transformed B-lymphoblastoid cell lines. Donor-de-
rived EBV-specific CTLs were transfused 45 days after allo-
geneic BM transplant in 50 patients at high risk of develop-
ing EBV lymphoma after T-cell-depleted transplantation
from a matched unrelated donor or a mismatched related
donor. None of the patients developed EBV-induced lym-
phoproliferative disease, whereas there was a cumulative
risk of 11 percent in patients who did not receive this treat-
ment. Moreover, two patients who were treated for clinically
evident EBV-induced lymphopro-liferative disease
achieved a prolonged remission after CTL transfusion.44
Remarkably, no significant toxicity or GVHD was observed
with this early posttransplant cell immunotherapy. The
development of donor-derived CTLs against other antigens
such mHA43,54 or the BCR-ABL fusion product42,59 is cur-
rently being investigated, and recently Falkenburg et al.71
reported the achievement of CR in a patient with acceler-
ated-phase CML by treatment with leukemia-reactive CTLs.
Cell immunotherapy after nonmyeloablative
preparative regimens
There is considerable evidence that the usual high-dose
preparative regimen frequently does not eradicate malig-
nancy. Moreover, its high-level toxicity restricts the use of
allogeneic HPC transplantation to young patients without
other medical illnesses. On the other hand, the high risk of
relapse after T-cell-depleted HPC transplantation, the even
greater risk after syngeneic HPC transplantation, and the
effectiveness of DLI in inducing CR in case of relapse after
allogeneic HPC transplantation indicate that the main therapeu-
tic component of allogeneic HPC transplantation may some-
times be due to the GVL effect rather than to the elimina-
tion of tumor cells through high doses of cytoreductive agents.
These observations led several centers to perform alloge-
neic HPC transplantation after nonmyeloablative (but suffi-
ciently immunosuppressive to allow engraftment), fludarabine-
based preparative regimens to induce a GVL effect. In this
approach, the posttransplant transient mixed chimerism
may be successfully completed by DLI.87,88
More recently, Storb89 and McSweeney90 and their cowork-
ers tried allogeneic HPC transplantation after a nonmyeloab-
lative but highly immunosuppressive (200 cGy total body
irradiation and cyclosporine plus mycophenolate mofetil)
preparative regimen to prevent host-versus-graft reactions
as well as GVHD. This approach permitted the achievement
of stable mixed chimerism in patients with either nonma-
lignant or malignant hematologic disease. Secondary DLI
in malignant disorders allowed the achievement of com-
plete donor chimerism. The potential advantage of this
technique would be a reduced risk of conditioning regi-
men-related toxicity, infection, or hemorrhage.
Although the preliminary results of “mini-transplants”
(transplant after a nonmyeloablative conditioning regimen)
are encouraging, long-term results in regard to leukemia-
free survival as well as the incidence of chronic GVHD re-
main to be achieved in appropriate studies before this ap-
proach can be considered effective and not merely anecdotal.
CONCLUSION
DLIs have been used increasingly to treat leukemic relapse
after allogeneic HPC transplantation, inducing CR in about
65 percent of the patients with CML and 25 percent of those
with AML or MDS. The risks of DLIs include transient mar-
row aplasia and acute and/or chronic GVHD. DLIs are not
associated with severe aplasia when given in early cytoge-
netic relapse, because residual hematopoiesis is still of
donor origin. It is possible to maintain a GVL effect with-
out GVHD by decreasing the number of T cells transfused
to 1 × 107 per kg or by depleting donor lymphocytes of CD8+
cells. Preliminary observations have been generated for a
number of newer approaches to DLI. In vitro transduction
of donor WBCs with a suicide gene to eliminate donor lym-
phocytes in case of severe GVHD, transfusion of donor lym-
phocytes for the prevention of relapse, development of
CTLs specifically recognizing tumor antigens, activation of
lymphocytes by cytokines, and DLI after allogeneic HPC
transplantation with a nonmyeloablative preparative regi-
men are promising new approaches that are currently be-
ing investigated.
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